Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
J Thorac Oncol. 2013 Sep;8(9):1212-4. doi: 10.1097/JTO.0b013e31829f6b4a.
Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict response to tyrosine kinase inhibitors. The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion in Asian populations than in whites. The prevalence of these mutations among North African patients is unknown. The objective of this study was to report the frequency and spectrum of EGFR mutations in a group of Moroccan patients with lung adenocarcinoma (AC).
Tumor specimens from 137 Moroccan patients with lung AC were selected to determine frequency and spectrum of EGFR mutations. Mutation detection techniques were polymerase chain reaction amplification and sequencing of exons 18, 19, 20, and 21.
The overall frequency of the EGFR mutation was 21%. Mutations were mainly detected in the exon 19 (69%), followed by exon 21 (21%) and exon 20 (7%), whereas mutations in the exon 18 were rare (3%). EGFR mutation rate was significantly higher in women and in never smokers.
Some one fifth of lung AC tumors in Moroccan patients harbor EGFR mutations. This mutation frequency is higher than that found in whites but lower than in Asian population. Further studies, in larger numbers of patients, are needed to confirm these findings.
表皮生长因子受体 (EGFR) 突变与非小细胞肺癌对酪氨酸激酶抑制剂的反应相关。EGFR 突变的频率具有种族依赖性，亚洲人群中的比例高于白种人。北非患者中这些突变的流行情况尚不清楚。本研究的目的是报告一组摩洛哥肺腺癌 (AC) 患者中 EGFR 突变的频率和谱。
选择 137 例摩洛哥肺 AC 患者的肿瘤标本，以确定 EGFR 突变的频率和谱。突变检测技术为外显子 18、19、20 和 21 的聚合酶链反应扩增和测序。
EGFR 突变的总体频率为 21%。突变主要在外显子 19 中检测到（69%），其次在外显子 21 中（21%）和外显子 20 中（7%），而外显子 18 中的突变很少（3%）。女性和从不吸烟者中 EGFR 突变率明显更高。
在摩洛哥患者的一些肺 AC 肿瘤中存在 EGFR 突变。这种突变频率高于白人，但低于亚洲人群。需要进一步研究，纳入更多患者来证实这些发现。
